We provide you with 20 years of free, institutional-grade data for ATHE stock, allowing you to gain comprehensive visibility into the fundamentals of the company. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of ATHE. Explore the full financial landscape of ATHE stock.
| Reported Date | CIK | Ticker | Type |
|---|
Alterity Therapeutics Limited(NASDAQ:ATHE) 
Alterity Therapeutics Limited researches and develops therapeutic drugs for the treatment of Parkinsonian's disease and other neurodegenerative diseases in Australia. The company's lead drug candidates is ATH434 that has completed Phase I clinical trial for the treatment of Parkinson's disease. It i...
Website: http://www.alteritytherapeutics.com
Founded: 1997
CEO: David Stamler
Sector: Healthcare
Industry: Biotechnology
Share this website to your friends
The information provided in this report about ATHE stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.